Latest Hotspot

FDA Approves Servier's VORANIGO®, First Targeted Treatment for Grade 2 IDH-mutant Glioma

12 August 2024
3 min read

Servier revealed that the U.S. Food and Drug Administration has given the green light to VORANIGO®, an inhibitor of isocitrate dehydrogenase-1 ((IDH1) and isocitrate dehydrogenase-2 (IDH2). This drug is intended for use in treating both adult and pediatric patients aged 12 and above who have Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, after undergoing surgery such as biopsy, sub-total resection, or gross total resection.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

图形用户界面, 文本, 应用程序

描述已自动生成

Gliomas are forms of brain cancer that impede normal brain activities and bring about a range of symptoms. Diffuse gliomas with IDH mutations are recognized as the most prevalent malignant primary brain tumors diagnosed in adults under the age of 50. These tumors are not curable with existing treatments and, without intervention, they continue to grow and invade healthy brain tissues.

"The approval of VORANIGO represents a significant advance in cancer treatment and is a landmark event for individuals with Grade 2 IDH-mutant glioma," stated Arjun H. Prasad, Chief Commercial Officer at Servier Pharmaceuticals.

"VORANIGO, the first major development in this particular disease in almost 25 years, provides patients with an unparalleled extension in progression-free survival. We are honored to bring this unique therapy to those in need and remain dedicated to introducing innovative targeted treatments for cancer patients," added Arjun H. Prasad.

In normal human cells, a set of genes known as isocitrate dehydrogenases assist in the breakdown of nutrients and energy production for cells. Mutations in IDH1 and IDH2 are linked to various cancers, preventing cells from differentiating into their destined specialized types.

"Individuals with Grade 2 IDH-mutant gliomas have long confronted the difficult reality of an incurable condition with very limited treatment options following surgery," remarked Ralph DeVitto, President & CEO of the American Brain Tumor Association. "The FDA approval of VORANIGO is a momentous advancement in glioma therapy, providing renewed optimism for patients and their families affected by this persistent disease."

The approval of VORANIGO is underpinned by findings from the critical Phase 3 INDIGO clinical trial documented in *The New England Journal of Medicine* and presented during the Plenary Session at the 2023 Annual Meeting of the American Society of Clinical Oncology, which demonstrated that VORANIGO considerably prolonged progression-free survival and the interval to the next intervention compared to a placebo.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of August 12, 2024, there are 6 investigational drugs for the IDH1 and IDH2 target, including 21 indications, 13 R&D institutions involved, with related clinical trials reaching 32, and as many as 2211 patents.

Vorasidenib represents a promising development in the pharmaceutical industry, with its potential to address a wide range of neoplastic and nervous system diseases, as well as other related disorders. Its advanced regulatory status and approval in the United States demonstrate its potential to positively impact patient care and treatment outcomes in the near future.

图形用户界面, 文本

描述已自动生成

NeuroBo, Dong-A ST, & ImmunoForge Collaborate on Monthly Obesity Treatment DA-1726
Latest Hotspot
3 min read
NeuroBo, Dong-A ST, & ImmunoForge Collaborate on Monthly Obesity Treatment DA-1726
9 August 2024
NeuroBo Pharmaceuticals, Dong-A ST, and ImmunoForge Sign Agreement to Collaborate on Developing a Monthly DA-1726 Formulation to Treat Obesity.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Aug 9
Pharma Frontiers
12 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Aug 9
9 August 2024
Aug 9th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
First U.S. Participant Joins Global Clinical Trial for Telitacicept in Myasthenia Gravis: A Milestone
Latest Hotspot
3 min read
First U.S. Participant Joins Global Clinical Trial for Telitacicept in Myasthenia Gravis: A Milestone
9 August 2024
The initial participant in the U.S. joins the phase III global multi-center clinical trial for telitacicept targeting myasthenia gravis, marking a significant milestone.
Read →
Elevation Oncology's Phase 1 Trial: Promising Early Results for EO-3021 in Advanced Non-Resectable/Metastatic Solid Tumors
Latest Hotspot
3 min read
Elevation Oncology's Phase 1 Trial: Promising Early Results for EO-3021 in Advanced Non-Resectable/Metastatic Solid Tumors
9 August 2024
Elevation Oncology Releases Encouraging Early Results from Phase 1 Trial of EO-3021 in Patients with Advanced Non-Resectable or Metastatic Solid Tumors.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.